#62 – Novel TheraPOOtics: The Microbiome, C. difficile, and LBPs

#62 – Novel TheraPOOtics: The Microbiome, C. difficile, and LBPs

Author: Society of Infectious Diseases Pharmacists August 26, 2022 Duration: 47:08

In this spore-tacular episode of Breakpoints, Drs. Anne Gonzales-Luna (@anniejayTX) and Paul Feuerstadt (@DrPaulGastro) join Dr. Rachel Britt (@rachelbpharmd) to discuss the microbiome, its relationship to C. difficile, and the new area of microbiota-based live biotherapeutic products (LBPs).

This podcast was sponsored by an unrestricted medical education grant from Ferring Pharmaceuticals.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.


Hosted by the Society of Infectious Diseases Pharmacists, Breakpoints is a podcast dedicated to the intricate and ever-evolving world of antimicrobial therapy. Each episode delves into the practical challenges and scientific nuances faced by pharmacists on the front lines of patient care, from interpreting susceptibility data and optimizing dosing strategies to navigating the complexities of antimicrobial stewardship. The conversations in this podcast bridge the gap between groundbreaking infectious diseases research and its direct application in clinical settings, offering insights that are both academically rigorous and immediately useful. You’ll hear expert discussions on new resistance patterns, evolving treatment guidelines, and the real-world implementation of life-saving protocols. Designed for healthcare professionals committed to precision medicine, Breakpoints provides a deeper understanding of how to effectively manage infections and improve patient outcomes. Tune in for thoughtful analysis and forward-thinking dialogue that defines the critical role of specialized pharmacists in public health.
Author: Language: en-us Episodes: 100

Breakpoints
Podcast Episodes
#134 – ESCMID Global Trials: PETER PEN and ASTARTE [not-audio_url] [/not-audio_url]

Duration: 1:03:15
Professor Mical Paul and Professor Jesús Rodríguez-Baño join Professor Josh Davis and Dr Erin McCreary for a special Breakpoints and Communicable podcast collaboration. This episode discusses the ‘Trials Run’ session at…
#130 – Dosing Consult: Amoxicillin [not-audio_url] [/not-audio_url]

Duration: 1:00:17
Drs. Ted Morton and Christine Lockowitz join Dr. Ryan Moenster to discuss all things amoxicillin, particularly in our pediatric patients. Our guests answer common questions, such as, what formulations should be used for…
#129 – Game of Spores: Blasto, Histo, Crypto, and Cocci [not-audio_url] [/not-audio_url]

Duration: 1:22:58
We’re starting 2026 off with a BLAST as Dr. Gregory Eschenauer and Dr. George R Thompson make their Breakpoints debut to discuss Blastomyces, Histoplasma, Coccidioides, and Cryptococcus. They join host Erin McCreary in r…
#128 – IDWeek 2025 Recap [not-audio_url] [/not-audio_url]

Duration: 1:35:54
Ring in the end of the year with our Breakpoints hosts and a review of all things IDWeek 2025! Join Drs. Erin McCreary, Julie Ann Justo, Whitney Buckel, and Ryan Moenster as they cover top late breaking abstracts, new st…
#127 – What’s Pneu in Community-Acquired Pneumonia Part 2 [not-audio_url] [/not-audio_url]

Duration: 52:27
As promised, our host Dr, Ryan Moenster is back and breaking down the recently published ATS pneumonia guidelines — what’s pneu, what’s controversial, and what it means for your antimicrobial game! Dr. Whitney Hartlage (…
#126 – What’s the Microbiome Gut to Do with It [not-audio_url] [/not-audio_url]

Duration: 1:08:15
Dr. Julie Ann Justo is joined by experts Drs. Krista Gens and Javier A. Villafuerte Gálvez as they dive deep into the gut microbiome and explore the latest therapeutic frontier for C. difficile infections. From bacteria…